We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+5.92%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$483M
AUM Growth
+$65.3M
Cap. Flow
+$58.7M
Cap. Flow %
12.16%
Top 10 Hldgs %
61.19%
Holding
32
New
12
Increased
7
Reduced
8
Closed
4

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$39.6M
2
BMY icon
Bristol-Myers Squibb
BMY
+$19.9M
3
IDXX icon
Idexx Laboratories
IDXX
+$19.7M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$19.1M
5
UNH icon
UnitedHealth
UNH
+$16M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$50.2M
2
PCVX icon
Vaxcyte
PCVX
+$31.1M
3
UTHR icon
United Therapeutics
UTHR
+$19.7M
4
NTRA icon
Natera
NTRA
+$16.7M
5
STVN icon
Stevanato
STVN
+$15M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LIVN icon
26
LivaNova
LIVN
$4.69B
$4.62M 0.96%
+99,700
New +$5.11M
PRAX icon
27
Praxis Precision Medicines
PRAX
$8.64B
$2.87M 0.59%
+37,269
New +$2.7M
FEMY icon
28
Femasys
FEMY
$9.21M
$33.7K 0.01%
1,530
– –
INSM icon
29
Insmed
INSM
$21.4B
– –
-143,920
Closed -$10.5M
PCVX icon
30
Vaxcyte
PCVX
$7.9B
– –
-271,922
Closed -$31.1M
PFE icon
31
Pfizer
PFE
$145B
– –
-1,732,935
Closed -$50.2M
UTHR icon
32
United Therapeutics
UTHR
$22B
– –
-54,926
Closed -$19.7M
1
2

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return
ECM
EagleClaw Capital Management Boston, Massachusetts $714M AUM 24.24% 1-Year Est. Return

Tri Locum Partners's Q4 2024 Portfolio in Review

As of Q4 2024, Tri Locum Partners held 32 positions worth $483M, up 16% from $417M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Tri Locum Partners deployed $58.7M of net new capital in Q4 2024, opening 12 new positions and adding to 7 existing holdings. Its largest new stake was Zimmer Biomet: 369,004 shares worth $39M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Natera, an estimated $16.7M trimmed.

  • Tri Locum Partners's largest Q4 2024 buy was Zimmer Biomet: 369,004 shares worth $39M.
  • Tri Locum Partners added most to Novo Nordisk in Q4 2024, an estimated $15.4M increase.
  • Tri Locum Partners's biggest Q4 2024 reduction was Natera, cutting an estimated $16.7M.
  • Tri Locum Partners fully exited Pfizer in Q4 2024, selling an estimated $50.2M.
  • Tri Locum Partners's ten largest holdings make up 61% of its $483M portfolio in Q4 2024.
  • Tri Locum Partners opened 12 new positions and closed 4 in Q4 2024.
  • Tri Locum Partners's portfolio value rose 16% quarter-over-quarter to $483M.

Based on Tri Locum Partners's 13F filing for Q4 2024, filed 14 Feb 2025.